Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 6, 2005, Pages 437-447

  Martino, Rodrigo ^a   Pérez Simón, José A ^b   Moreno, Estela ^c   Queraltó, José M ^c   Caballero, Dolores ^b   Mateos, Marivi ^b   Sureda, Anna ^a   Cañizo, Consuelo ^b   Brunet, Salut ^a   Briones, Javier ^a   Vazquez, Lourdes ^b   Clopés, Ana ^c   San Miguel, Jesús F ^b   Sierra, Jorge ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Allogeneic peripheral blood stem cell transplantation; Busulfan pharmacokinetics; Reduced intensity

Indexed keywords

ACICLOVIR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIINFECTIVE AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; FOLINIC ACID; GAMMA GLUTAMYLTRANSFERASE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENYTOIN; PREDNISONE;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DONOR; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; GRAFT SURVIVAL; GRANULOCYTE; HERPES; HIGH RISK PATIENT; HUMAN; INFECTION RISK; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYCOSIS; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOPROLIFERATIVE DISORDER; PREDICTION; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; SEIZURE; SIBLING; SIDE EFFECT; STEADY STATE; T LYMPHOCYTE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; BUSULFAN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 19944425172     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.03.003     Document Type: Article

References (62)

1. H.J. Deeg P. Guardiola Allogeneic hemopoietic stem cell transplantation in patients with myelodysplastic syndrome or myelofibrosis Int J Hematol 76 suppl 2 2002 29-34
2. H.J. Deeg H.M. Shulman J.E. Anderson et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age Blood 95 2000 1188-1194
3. J. Sierra W.S. Perez C. Rozman et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia Blood 100 2002 1997-2004
4. T. de Witte J. Hermans J. Vossen et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Br J Haematol 110 2000 620-630
5. C. Ferry G. Socie Busulfan-cyclophosphamide versus total body irradiation-cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: What have we learned? Exp Hematol 31 2003 1182-1186
6. R. Diaconescu C.R. Flowers B. Storer et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors Blood 104 2004 1550-1558
7. M. Hassan The role of busulfan in bone marrow transplantation Med Oncol 16 1999 166-176
8. P.F. Thall R.E. Champlin B.S. Andersson Comparison of 100-day mortality rates associated with i.v busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects Bone Marrow Transplant 33 2004 1191-1199
9. S.P. Dix J.R. Wingard R.E. Mullins et al. Association of busulfan area under the curve with veno-occlusive disease following BMT Bone Marrow Transplant 17 1996 225-230
10. L.B. Grochow Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens Semin Oncol 20 4 suppl 4 1993 18-25
11. J.T. Slattery T.F. Kalhorn G.B. McDonald et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients J Clin Oncol 14 1996 1484-1494
12. J.S. McCune J.P. Gibbs J.T. Slattery Plasma concentration monitoring of busulfan: Does it improve clinical outcome? Clin Pharmacokinet 39 2000 155-165
13. J.P. Radich T. Gooley W. Bensinger et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen Blood 102 2003 31-35
14. H.J. Deeg B. Storer J.T. Slattery et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome Blood 100 2002 1201-1207
15. M. Bornhauser B. Storer J.T. Slattery et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells Blood 102 2003 820-826
16. M. De Lima D. Couriel P.F. Thall et al. Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS Blood 104 2004 857-864
17. J.A. Russell H.T. Tran D. Quinlan et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes Biol Blood Marrow Transplant 8 2002 468-476
18. P.A. McSweeney D. Niederwieser J.A. Shizuru et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 2001 3390-3400
19. D. Niederwieser M. Maris J.A. Shizuru et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases Blood 101 2003 1620-1629
20. R. Martino M.D. Caballero C. Canals et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: Results of a prospective multicentre study Br J Haematol 115 2001 653-659
21. R. Martino M.D. Caballero J. de la Serna et al. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant Bone Marrow Transplant 30 2002 63-68
22. R. Chakraverty K. Peggs R. Chopra et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen Blood 99 2002 1071-1078
23. P.D. Kottaridis D.W. Milligan R. Chopra et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood 96 2000 2419-2425
24. S. Giralt P.F. Thall I. Khouri et al. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 97 2001 631-637
25. I.F. Khouri R.M. Saliba S.A. Giralt et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality Blood 98 2001 3595-3599
26. S. Slavin A. Nagler E. Naparstek et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 1998 756-763
27. R. Or M.Y. Shapira I. Resnick et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase Blood 101 2003 441-445
28. R. Childs E. Clave N. Contentin et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses Blood 94 1999 3234-3241
29. A.M. Carella S. Giralt S. Slavin Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia Haematologica 85 2000 304-313
30. A.M. Carella E. Lerma M.T. Corsetti et al. Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone Br J Haematol 103 1998 565-567
31. H. Bertz K. Potthoff J. Finke Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia J Clin Oncol 21 2003 1480-1484
32. M. De Lima A. Anagnostopoulos M. Munsell et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood 104 2004 865-872
33. A.Y. Ho M. Kenyon I. El Hemaidi S. Devereux A. Pagliuca G.J. Mufti Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: Survival does not plateau until after day 200 Blood 101 2003 779-780
34. G.G. Laport Nonmyeloablative allogeneic stem cell transplantation for acute leukemia Curr Hematol Rep 2 2003 49-56
35. H.G. Sayer M. Kroger J. Beyer et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: Disease status by marrow blasts is the strongest prognostic factor Bone Marrow Transplant 31 2003 1089-1095
36. R. Martino M.D. Caballero J.A. Simon et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes Blood 100 2002 2243-2245
37. D. Valcarcel R. Martino D. Caballero et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning Bone Marrow Transplant 31 2003 387-392
38. M. Bornhauser C. Thiede U. Schuler et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: Durable engraftment without antithymocyte globulin Bone Marrow Transplant 26 2000 119-125
39. J.T. Slattery R.A. Clift C.D. Buckner et al. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation Blood 89 1997 3055-3060
40. J.T. Slattery J.E. Sanders C.D. Buckner et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 16 1995 31-42
41. P. Greenberg C. Cox M.M. LeBeau et al. International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079-2088
42. A. Urbano-Ispizua N. Schmitz T. de Witte et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Definitions and current practice in Europe Bone Marrow Transplant 29 2002 639-646
43. S. Suciu F. Mandelli T. de Witte et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/ GIMEMAAML-10 trial Blood 102 2003 1232-1240
44. D. Przepiorka D. Weisdorf P. Martin et al. 1994 Consensus Conference on Acute GVHD Grading Bone Marrow Transplant 15 1995 825-828
45. K.M. Sullivan E. Agura C. Anasetti et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation Semin Hematol 28 1991 250-259
46. J.A. Perez-Simon D. Caballero M. Diez-Campelo et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation Leukemia 16 2002 1423-1431
47. J. Gabert E. Beillard V.H. van der Velden et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program Leukemia 17 2003 2318-2357
48. R. Martino M.D. Caballero C. Canals et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation Bone Marrow Transplant 28 2001 341-347
49. R. Manteiga R. Martino A. Sureda et al. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: A single-center experience Bone Marrow Transplant 22 1998 899-904
50. P. Reusser H. Einsele J. Lee et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation Blood 99 2002 1159-1164
51. J.P. Klein J.D. Rizzo M.J. Zhang N. Keiding Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling Bone Marrow Transplant 28 2001 1001-1011
52. J.P. Klein J.D. Rizzo M.J. Zhang N. Keiding Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis Bone Marrow Transplant 28 2001 909-915
53. J.A. Perez-Simon M. Diez-Campelo R. Martino et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation Blood 102 2003 1108-1113
54. M. Subira A. Sureda I. Ancin et al. Allogeneic stem cell transplantation with reduced-intensity conditioning is potentially feasible as an outpatient procedure Bone Marrow Transplant 32 2003 869-872
55. L.C. Feinstein B.M. Sandmaier U. Hegenbart et al. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission Br J Haematol 120 2003 281-288
56. S. Giralt A. Anagnostopoulos M. Shahjahan R. Champlin A. Anagnastopoulos M. Shahjahanan Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes Semin Hematol 39 2002 57-62
57. N. Kroger M. Bornhauser G. Ehninger et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia Ann Hematol 82 2003 336-342
58. D.C. Taussig A.J. Davies J.D. Cavenagh et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting J Clin Oncol 21 2003 3060-3065
59. R. Wong S.A. Giralt T. Martin et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment of myeloid malignancies in patients older than 55 years Blood 102 2003 3052-3059
60. B.S. Andersson A. Kashyap D. Couriel et al. Intravenous busulfan in pretransplant chemotherapy: Bioavailability and patient benefit Biol Blood Marrow Transplant 9 2003 722-724
61. U.S. Schuler U.D. Renner F. Kroschinsky et al. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation Br J Haematol 114 2001 944-950
62. C.B. Williams S.D. Day M.D. Reed et al. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies Biol Blood Marrow Transplant 10 2004 614-623